急性髓系白血病的表观遗传学治疗研究进展

Advances of epigenetic therapy in acute myeloid leukemia

随着二代测序等技术的发展,急性髓系白血病(acute myeloid leukemia,AML)中发现了越来越多与表观遗传调控相关的基因存在突变、易位或缺失。这些事件的发生经常与AML发病、耐药和预后不良有关。表观遗传调控主要通过DNA甲基化、组蛋白修饰、非编码RNA等机制调节,而这些调控方式在AML发生、发展中发挥重要作用。临床上,相较于传统化疗,调控表观遗传的药物联合化疗治疗AML取得显著疗效,明显提高了患者的缓解率。因此,为了更好地理解并应用调控表观遗传学的药物治疗AML,本文就AML表观遗传学治疗的研究进展予以综述。

With the development of second-generation sequencing and other technologies,more and more epigenetic regulation-related genes have been found mutations or deletions in acute myeloid leukemia(AML).These factors are often associated with treatment resistance and poor prognosis.Epigenetic regulation is mainly regulated through DNA methylation,histone modification,non-coding RNA and other mechanisms,which play an important role in the occurrence and development of AML.In clinical practice,compared with traditional chemotherapy,epigenetic drugs combined with chemotherapy have achieved significant efficacy in the treatment of AML,and improved the remission rate of patients.This article reviews the research progress of epigenetic therapy for AML.